{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:06Z","timestamp":1790686206051,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.hoc.2013.01.006","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T08:39:43Z","timestamp":1375346383000},"page":"851-860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"27","author":[{"given":"Nitin","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2013.01.006_bib1","series-title":"SEER cancer statistics review, 1975-2009 (Vintage 2009 Populations)","author":"Howlader","year":"2012"},{"issue":"5","key":"10.1016\/j.hoc.2013.01.006_bib2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2010.32.3865","article-title":"Update on therapy of chronic lymphocytic leukemia","volume":"29","author":"Gribben","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2013.01.006_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2013.01.006_bib4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.hoc.2013.01.006_bib5","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2013.01.006_bib6","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2013.01.006_bib7","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","article-title":"Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2013.01.006_bib8","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","article-title":"Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia","volume":"98","author":"O'Brien","year":"2003","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.hoc.2013.01.006_bib9","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1470-2045(11)70242-X","article-title":"Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial","volume":"12","author":"Elter","year":"2011","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2013.01.006_bib10","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2013.01.006_bib11","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2013.01.006_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1146\/annurev.immunol.21.120601.141018","article-title":"B\u00a0cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor","volume":"21","author":"Chiorazzi","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"10.1016\/j.hoc.2013.01.006_bib13","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2003-12-4312","article-title":"Chronic lymphocytic leukemia: revelations from the B-cell receptor","volume":"103","author":"Stevenson","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2013.01.006_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2013.01.006_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/asheducation-2011.1.96","article-title":"Nurture versus nature: the microenvironment in chronic lymphocytic leukemia","volume":"2011","author":"Burger","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.hoc.2013.01.006_bib16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2013.01.006_bib17","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"issue":"2\u20133","key":"10.1016\/j.hoc.2013.01.006_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/IR:23:2-3:147","article-title":"Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase","volume":"23","author":"Khan","year":"2001","journal-title":"Immunol Res"},{"key":"10.1016\/j.hoc.2013.01.006_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-065X.2000.imr017504.x","article-title":"The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective","volume":"175","author":"Satterthwaite","year":"2000","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.hoc.2013.01.006_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","article-title":"Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells","volume":"152","author":"Smith","year":"1994","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"10.1016\/j.hoc.2013.01.006_bib21","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1002\/eji.1830241228","article-title":"Expression of Bruton's tyrosine kinase protein within the B cell lineage","volume":"24","author":"Genevier","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.hoc.2013.01.006_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev.immunol.021908.132649","article-title":"Primary B cell immunodeficiencies: comparisons and contrasts","volume":"27","author":"Conley","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"13","key":"10.1016\/j.hoc.2013.01.006_bib23","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","article-title":"Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia","volume":"100","author":"Chen","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2013.01.006_bib24","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Rosenwald","year":"2001","journal-title":"J\u00a0Exp Med"},{"issue":"7277","key":"10.1016\/j.hoc.2013.01.006_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.hoc.2013.01.006_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI200522094","article-title":"Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis","volume":"115","author":"Contri","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.hoc.2013.01.006_bib27","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2012.24","article-title":"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration","volume":"26","author":"Hoellenriegel","year":"2012","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.hoc.2013.01.006_bib28","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2013.01.006_bib29","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2009-07-233692","article-title":"Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia","volume":"115","author":"Buchner","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2013.01.006_bib30","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2013.01.006_bib31","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2013.01.006_bib32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2013.01.006_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"issue":"29","key":"10.1016\/j.hoc.2013.01.006_bib34","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"23","key":"10.1016\/j.hoc.2013.01.006_bib35","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2013.01.006_bib36","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in\u00a0vitro and in\u00a0vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2013.01.006_bib37","unstructured":"Advani RH, Sharman JP, Smith SM, et\u00a0al. The Btk Inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed\/refractory B cell malignancies: final results from a phase I study. 11th International Conference on Malignant Lymphoma Meeting Abstract. Lugano, Switzerland. June 15, 2011. p. 153a."},{"key":"10.1016\/j.hoc.2013.01.006_bib38","doi-asserted-by":"crossref","unstructured":"O'Brien S, Burger JA, Blum KA, et\u00a0al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): follow-up of\u00a0a phase Ib\/II study. American Society of Hematology Annual Meeting Abstracts. San Diego, USA. December 13, 2011. p. 983a.","DOI":"10.1182\/blood.V118.21.983.983"},{"key":"10.1016\/j.hoc.2013.01.006_bib39","unstructured":"O\u2019Brien S, Furman R, Coutre S, et\u00a0al. The Bruton\u2019s Tyrosine kinase inhibitor ibrutinib is highly active and tolerable in relapsed or refractory and treatment naive CLL patients, updated results of a phase IB\/II study. European Hematology Meeting Annual Abstracts. Amsterdam, The Netherlands. June 16, 2012. p. 542a."},{"key":"10.1016\/j.hoc.2013.01.006_bib40","doi-asserted-by":"crossref","unstructured":"Jaglowski SM, Jones JA, Flynn JM, et\u00a0al. A phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases. American Society of Clinical Oncology Annual Meeting Abstracts. Chicago, USA. June 4, 2012. p. 6508a.","DOI":"10.1200\/jco.2012.30.15_suppl.6508"},{"key":"10.1016\/j.hoc.2013.01.006_bib41","unstructured":"Brown J, Barrientos J, Flinn I, et\u00a0al. The Bruton\u2019s tyrosine kinase (Btk) inhibitor ibrutinib combined with bendamustine and rituximab is active and tolerable in patients with relapsed\/refractory CLL, interim results of a phase Ib\/II study. European Hematology Meeting Annual Abstracts. Amsterdam, The Netherlands. June 16, 2012. p. 543a."},{"key":"10.1016\/j.hoc.2013.01.006_bib42","doi-asserted-by":"crossref","unstructured":"Wang L, Martin P, Blum KA, et\u00a0al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. American Society of Hematology Annual Meeting Abstracts. San Diego, USA. December 13, 2011. p. 442a.","DOI":"10.1182\/blood.V118.21.442.442"},{"key":"10.1016\/j.hoc.2013.01.006_bib43","unstructured":"Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01578707?term=ibrutinib&rank=6. Accessed August 25, 2012."}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858813000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858813000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:59:49Z","timestamp":1760183989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858813000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0889858813000075"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2013.01.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2013.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}